Alendronate treatment in osteogenesis imperfecta


MADENCİ E.

JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, cilt.12, ss.53-56, 2006 (SCI İndekslerine Giren Dergi) identifier

  • Cilt numarası: 12 Konu: 2
  • Basım Tarihi: 2006
  • Doi Numarası: 10.1097/01.rhu.0000208490.22492.09
  • Dergi Adı: JCR-JOURNAL OF CLINICAL RHEUMATOLOGY
  • Sayfa Sayısı: ss.53-56

Özet

Aims: Osteogenesis imperfecta (01) is a chronic, disabling condition characterized by bone fragility resulting from defective production of type I collagen. Pamidronate therapy is the most extensively studied treatment and has proved beneficial. Our objective was to evaluate the effect of alendronate, a more potent bisphosphonate than pamidronate, in OI.